Saint Louis University

Indalo Therapeutics, Inc.

Peter G Ruminski

David W Griggs

Scott D Seiwert

Marvin Jay Meyers

Stacy D Arnett

David Collier Wood

Matthew P Yates

The disclosure provides for new epidermal growth factor (EGF)-based reagents that have been modified by fatty acid conjugation. Method of using such agents to treatment Short Bowel Syndrome (SBS) are also described.

Fatty acid modified human epidermal growth factor

The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins &#x3b1;&#x3bd;&#x3b2;&#x3b9; and/or &#x3b1;5&#x3b2;&#x3b9;. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins &#x3b1;&#x3bd;&#x3b2;3, &#x3b1;&#x3bd;&#x3b2;5, &#x3b1;&#x3bd;&#x3b2;6, &#x3b1;&#x3bd;&#x3b2;8, and/or &#x3b1;IIb&#x3b2;3. 

Integrin antagonists

The present disclosure provides pharmaceutical agents of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.

Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists

Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

Beta amino acid derivatives as integrin antagonists

Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein X is bromo or iodo, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

Growing community of inventors

Wildwood, MO, United States of America

Peter G Ruminski